Ron Bentsur Purchases Shares of Nuvectis Pharma

Ron Bentsur, the Chairman and CEO of Nuvectis Pharma, Inc. (NasdaqCM: NVCT), bought 12,500 shares of the company on June 30, 2026. The purchase was made at an average price of $20 per share, amounting to a total value of $250,000.

Insider Buying and Selling at Nuvectis Pharma, Inc.

In addition to Ron Bentsur's purchase, several other insiders made significant buys. Marlio Charles Mosseri acquired 50,000 shares at $18.32 each on the same day. Earlier in the month, Kenneth Hoberman, James III Oliviero, Matthew Kaplan, and Juan Sanchez each bought 35,000 shares, although the transaction prices for these purchases were not disclosed.

Other Institutional Activity in Nuvectis Pharma

Several institutional investors have also been active with Nuvectis Pharma shares. BlackRock, Inc. reduced its holdings by 18,364 shares, leaving it with 764,441 shares valued at about $5.91 million. Vanguard Capital Management LLC opened a new position with 659,879 shares worth approximately $5.10 million. Meanwhile, Iridian Asset Management LLC/CT increased its stake by 65,437 shares, holding a total of 651,757 shares valued at around $5.04 million. Occam Crest Management LP and Geode Capital Management, LLC also increased their holdings by 27,147 and 20,081 shares, respectively.

Nuvectis Pharma, Inc. Stock Down 18.0%

Shares of Nuvectis Pharma traded near $19.46 on Wednesday. The company, with a market cap of approximately $487.8 million, operates in the biotechnology sector. It has a 52-week low of $5.55 and a high of $29.27, with a 50-day moving average of $11.73 and a 200-day moving average of $8.51. The company's forward P/E ratio is not meaningful due to its unprofitability, and it has a beta of -0.072.

Analysts Set New Price Targets

On June 22, 2026, HC Wainwright & Co. maintained their buy rating for Nuvectis Pharma with a price target of $39. Analysts have a strong buy recommendation for the stock, with a mean target price of $29.2 across five opinions.

About Nuvectis Pharma

Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing precision medicines for treating serious conditions in oncology. Based in Fort Lee, New Jersey, the company is working on NXP900, a small molecule drug in a Phase 1b clinical trial aimed at treating solid tumors. Founded in 2020 and led by CEO Ron Bentsur, the company aims to address unmet medical needs in cancer treatment.

Bottom Line

Ron Bentsur's recent purchase of Nuvectis Pharma shares underscores his confidence in the company's prospects. Investors often track insider buys as a signal of potential growth. While the stock has seen significant activity from both insiders and institutional investors, it's important to remember that these transactions reflect past actions and may not indicate future performance.